Merck Reaffirms Commitment To Consumer Care In Restructuring
This article was originally published in The Tan Sheet
Executive Summary
Merck says it remains committed to retaining consumer care and animal health, though it continues to evaluate the businesses. Competitors such as Pfizer and Bristol-Myers Squibb successfully spun out non-pharma assets following similar restructurings.
You may also be interested in...
In Brief: Furness in new CDER role; Oxytrol for Women at retail; advisories on drug-tainted sex enhancers; senators want energy drink restrictions
Furness takes on new CDER role; Merck’s Oxytrol OTC arrives at retail; FDA issues advisory on drug-tainted sex enhancers; senators want energy drink restrictions; more news In Brief.
FDA Needs More Time To Review Sugammadex Inspection Report, Cancels Advisory Committee
Merck’s anesthesia reversal agent, which was deemed “not approvable” in 2008, faces another setback as FDA cancels its July 18 advisory committee meeting to allow more time to review clinical trial site inspection data.
Consumer Division Divestments Would Spotlight Firms’ Value – Analysts
Germany’s Merck KGaA could join the ranks of firms like Pfizer potentially looking to leave the consumer health care product business, market analysts argue.